Systemic therapy of bronchioloalveolar carcinoma: Results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma

Journal of Thoracic Oncology

Volumn 1, Issue 9 SUPPL., 2006, Pages

  Kris, Mark G ^a   Giaccone, Giuseppe ^b   Davies, Angela ^c   Fukuoka, Masahiro ^d   Garfield, David H ^e   Jassem, Jacek ^f   Quoix, Elisabeth A ^g   Sandler, Alan B ^h   Scagliotti, Giorgio V ⁱ   Van Meerbeeck, Jan P ^j   West, Howard ^k  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^f MEDICAL UNIVERSITY OF GDANSK   (Poland)

^g Service de Pneumologie Lyautey   (France)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j GHENT UNIVERSITY HOSPITAL   (Belgium)

^k SWEDISH MEDICAL CENTER   (United States)

more..

Author keywords

Adenocarcinoma; Bronchioloalveolar carcinoma; Epidermal growth factor receptor; Erlotinib; Gefitinib

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; CG 8123; CISPLATIN; CORTICOSTEROID; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INDOMETACIN; MACROLIDE; PACLITAXEL; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

BRONCHORRHEA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG DOSE REDUCTION; GENE MUTATION; HISTOLOGY; HUMAN; HYPOXEMIA; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG INFILTRATE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SENSITIVITY ANALYSIS; SMOKING; SPUTUM; SYSTEMIC THERAPY; WORLD HEALTH ORGANIZATION; CANCER STAGING; COMPARATIVE STUDY; CONSENSUS DEVELOPMENT; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MALE; MORTALITY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34247884504     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/s1556-0864(15)30007-1     Document Type: Conference Paper

References (30)

1. World Health Organization. Pathology and genetics of tumors of the lung, pleura, thymus and heart. In Travis WD, Brambilla E, Muller-Hermelink H, Harris C (Eds.), World Health Organization Classification of Tumors. Lyon: IARC Press, 2004, p 38.
2. Ebright MI, Zakowski MF, Martin J, et al. Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma. Ann Thorac Surg 2002;74:1640-1646.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Eng J Med 2002;346:92-98.
4. West HL, Crowley JJ, Vance RB, et al. Advanced bronchioloalveolar carcinoma: A phase II trial of paclitaxel by 96-hour infusion (SWOG 9714). Ann Oncol 2005;16:1076-1080.
5. Scagliotti GV, Smit E, Bosquee L, et al. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer 2005;50:91-96.
6. West HL, Franklin WA, McCoy J, et al. Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group (SWOG) study S0126. J Clin Oncol 2006;24:1807-1813.
7. Franklin WA, Gumerlock PH, Crowley J. EGFR, HER2 and ERB-B pathway activation in bronchioloalveolar carcinoma (BAC): analysis of SWOG 9417 and lung SPORE tissue samples. Proc Am Soc Clin Oncol 2003;22:620.
8. Hirsch FR, Scagliotti GV, Langer CJ, Varella-Garcia M, Franklin WA. Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41 (Suppl 1):S29-S42.
9. Franklin WA, Chansky K, Gumerlock PH, et al. Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126) (Abstract). Proc ASCO 2004;7015:618.
10. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group study. J Clin Oncol 2005;23:6838-6845.
11. Kris MG, Sandler A, Miller V, et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar cacinoma (BAC). Proc Am Soc Clin Oncol 2004;22:631S.
12. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
13. Wislez M, Massiani MA, Milleron B, et al. Clinical characteristics of pneumonic-type adenocarcinoma of the lung. Chest 2003;123:1868-1877.
14. Cadranel J, Debove P, Quoix E, et al. Phase II study of gefitinib (IRESSA) administered as first time treatment in patients with nonresectable, pneumonic-type adenocarcinoma (P-ADC). In Lung Cancer. Barcelona, Spain: International Association for the Study of Lung Cancer, 2005, p S367.
15. Kubba S, Adak S, Schiller J, et al. Phase I trial of adenovirus p53 in bronchioloalveolar cell lung carcinoma (BAC) administered by bronchoalveolar lavage (BAL). Proc Am Soc Clin Oncol 2000;19:487a.
16. Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003;21:624-630.
17. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004;96:326-331.
18. Van Zandwijk N, Jassem E, Dubbelmann R, Braat MCP, Rumke P. Aerosol application of interferon-alpha in the treatment of bronchioloalveolar carcinoma. Eur J Cancer Clin Oncol 1990;26:738-740.
19. Sharma S, White DR, Kris M, et al. A multicenter phase I clinical and pharmacologic study of inhaled doxorubicin (Resmycin) in adults with advanced solid tumors affecting the lungs. Proc Am Soc Clin Oncol 2002:302a.
20. Homma S, Kawabata M, Kishi K, et al. Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma. Chest 1999;115:1465-1468.
21. Tamaoki J, Kohri K, Isono K, Nagai A. Inhaled indomethacin in bronchorrhea in bronchioloalveolar carcinoma: role of cyclooxygenase. Chest 2000;117:1213-1214.
22. Nakajima E, Hirano T, Ikeda N, et al. K-ras mutation in sputum of primary lung cancer patients does not always reflect that of cancerous cells. Int J Onc 2001;18:105-110.
23. Desaki M, Takizawa H, Ohtoshi T, et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000;267:124-128.
24. Suga T, Sugiyama Y, Fujii T, Kitamura S. Bronchioloalveolar carcinoma with bronchorrhea treated with erythromycin. Eur Resp J 1994;7:2249-2251.
25. Kitazaki T, Soda H, Doi S, Nakano H, Nakamura Y, Kohno S. Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells. Lung Cancer 2005;50:19-24.
26. Takao M, Inoue K, Watanabe F, et al. Successful treatment of persistent bronchorrhea by gefitinib in a case with recurrent bronchioloalveolar carcinoma: a case report. World J Surg Oncol 2003;1:8-11.
27. Yano S, Kanematsu T, Miki T, et al. A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa"(1)). Cancer Sci 2003;94:453-458.
28. Milton D, Kris MG, Gomez J, Feinstein M. Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa). Support Care Cancer 2005;13:70-72.
29. Kitazaki T, Fukuda M, Soda H, Kohno S. Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports. Lung Cancer 2005;49:125-128.
30. Sandler A, Kris MG, Miller VA, et al. Phase II trial of erlotinib in patients with bronchioloalveolar carcinoma. Lung Cancer 2005;49(Suppl 2):S38.